Pharma News

Colombia boosts health sovereignty through public-private biotech collaboration agreement

Home/Pharma News | Posted 07/04/2025

On 27 February 2025, Colombia's Ministry of Health, the National Institute of Health, and VaxThera announced a pivotal agreement to enhance research, development, and production of biologicals and health technologies. This collaboration aims to strengthen health sovereignty, advance biotechnology, and improve emergency response capabilities.

Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News | Posted 18/02/2025

Bio-Thera Solutions (Bio-Thera) has partnered with Tabuk Pharmaceutical Manufacturing (Tabuk) to exclusively manufacture, distribute, and market BAT2206, a biosimilar to Stelara (ustekinumab), in Saudi Arabia. Simultaneously, Bio-Thera expanded its collaboration with SteinCares, granting exclusive rights to distribute an additional biosimilar in Latin America, reinforcing its global biosimilar strategy.

Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News | Posted 06/02/2025

Klinge Biopharma (Klinge) and Teva Pharmaceuticals (Teva) formed a semi-exclusive agreement for the commercialization of Formycon’s FYB203 biosimilar to Eylea (aflibercept) in Europe, while MS Pharma partners for the MENA (Middle East and North Africa) commercialization of FYB202, a biosimilar to Stelara (ustekinumab).

Biosimilars thrive as China’s biotech industry gains momentum

Home/Pharma News | Posted 21/01/2025

China is emerging as a global biotech leader, attracting significant investment and partnerships from multinational pharmaceutical companies. Its innovative therapies and biosimilars are gaining international traction, reshaping the industry despite ongoing challenges.

Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News | Posted 15/01/2025

The World Health Organization (WHO) has launched the ‘Greener Pharmaceuticals’ Regulatory Highway’ initiative to promote sustainability in the pharmaceutical sector. The initiative calls for innovative regulatory practices, sustainable manufacturing, and eco-friendly innovations to reduce the environmental impact of healthcare products.

Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals

Home/Pharma News | Posted 08/01/2025

On 3 December 2024, Coherus BioSciences announced that it will sell its Udenyca (pegfilgrastim) franchise, a biosimilar version of Amgen’s Neulasta, to India-based drugmaker Intas Pharmaceuticals.

Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement

Home/Pharma News | Posted 20/11/2024

On 31 October 2024, it was announced that Chicago-based Meitheal Pharmaceuticals had expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co, to market and distribute three biosimilars in the US. These include the oncology biosimilars pegfilgrastim and filgrastim, as well as fertility treatment follitropin alpha.

EMS proposes merger with Hypera to form Brazil's largest drugmaker

Home/Pharma News | Posted 13/11/2024

On 21 October 2024, Brazilian pharmaceutical giant EMS proposed a partnership with competitor Hypera Pharma, setting a course to become Brazil’s largest drug manufacturer.

Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206

Home/Pharma News | Posted 05/11/2024

In October 2024, China based Bio-Thera Solutions (Bio-Thera) and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Johnson & Johnson’s Stelara (ustekinumab).

Advances for Biocon Biologics’ Stelara and Eylea biosimilars

Home/Pharma News | Posted 24/09/2024

Biocon Biologics (Biocon) settled patent disputes with Janssen to commercialize Bmab 1200, a biosimilar of Stelara (ustekinumab), in several markets, including Europe and Canada. Additionally, Biocon received UK marketing authorization for Yesafili, its biosimilar of Eylea (aflibercept).

China’s Hasten Biopharma acquires 14 products from Celltrion

Home/Pharma News | Posted 10/09/2024

In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.

Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus

Home/Pharma News | Posted 16/07/2024

On 27 June 2024, Coherus BioSciences announced that is has divested Yusimry (aflibercept-jbvf), an adalimumab biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF) in a US$40 million deal.

Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil

Home/Pharma News | Posted 12/06/2024

By mid-April 2024, India-based Biocon Biologics signed an exclusive licensing and supply agreement that will allow Brazil’s Biomm SA to commercialise semaglutide, which is used to control type-2 diabetes in adults and has been repurposed for obesity management.

Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements

Home/Pharma News | Posted 05/06/2024

In May 2024, Klinge Biopharma announced an exclusive licensing and supply agreement with MS Pharma for FYB203 commercialization in the Middle East and North Africa (MENA) region. Previously, in April 2024, mAbxience and Teva Pharmaceuticals signed a strategic licensing agreement for a biosimilar candidate for oncology treatment.

Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab

Home/Pharma News | Posted 28/05/2024

In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.

Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM

Home/Pharma News | Posted 14/05/2024

Bio-Thera Solutions (Bio-Thera) announced in March 2024 a licensing agreement with SteinCares to market two biosimilars in Brazil and the rest of the region.

Formycon launches biosimilar ranibizumab Ravegza in Saudi, Gedeon Richter invests

Home/Pharma News | Posted 07/05/2024

In March 2024, Formycon and MS Pharma announced that their FYB201/ranibizumab Ravegza, a biosimilar to Lucentis, has received marketing authorization from the Saudi Food and Drug Authority.

mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta

Home/Pharma News | Posted 09/04/2024

mAbxience announced in February 2024 a pivotal agreement with Biosidus to manufacture Agalsidase Beta. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease.

Biosimilars lawsuits and settlement updates for Regeneron and Alvotech

Home/Pharma News | Posted 22/03/2024

In January 2024, Regeneron filed a lawsuit against Amgen in the federal court in Los Angeles, alleging Amgen's proposed biosimilar of Regeneron's Eylea (aflibercept) violates patent rights. Additionally, in February 2024, Iceland-based Alvotech announced the anticipated global market entry dates for AVT04, a ustekinumab biosimilar to Stelara, following its settlement with Johnson & Johnson.

The journey of Pectuna pertuzumab follow-on biological in Iran

Home/Pharma News | Posted 29/02/2024

Pertuzumab is a monoclonal antibody (mAb) that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation. It is a pivotal therapeutic in oncology, targeting the overexpressed HER2 protein, particularly in breast cancer [1].

Sandoz US acquisition of ranibizumab biosimilar from Coherus

Home/Pharma News | Posted 09/02/2024

On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.

Fiocruz and Pfizer sign agreement for generic of Xeljanz

Home/Pharma News | Posted 30/01/2024

Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.

Biocon to commercialize biosimilars in 31 European countries

Home/Pharma News | Posted 23/01/2024

Biocon Biologics has successfully integrated Viatris’ biosimilars business in 31 European countries, it was announced in late November 2023.

J&J lawsuits settled over ustekinumab biosimilars

Home/Pharma News | Posted 24/07/2023

Johnson & Johnson (J&J), the maker of Stelara (ustekinumab), settled two lawsuits, one against Amgen, and the other against Alvotech and Teva Pharmaceuticals. Both lawsuits were over proposed ustekinumab biosimilars for the treatment of autoimmune conditions. These were settled in May and June 2023, respectively.

Genfar: Eurofarma's new generic brand in Latin America

Home/Pharma News | Posted 12/12/2023

Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product

Home/Pharma News | Posted 28/11/2023

Ocrelizumab is a therapeutic monoclonal antibody (mAb) that represents a different scientific approach to treating multiple sclerosis (MS). It is a humanized anti-CD20 mAb that targets CD20 marker on B lymphocytes, a typo of immune cell that plays a key role in the disease and serves as an immunosuppressive drug. Ocrelizumab binds selectively to CD20, which is expressed on the membrane of B cells. When ocrelizumab binds to CD20 on B cells, these cells are eliminated by antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.

Insulin biosimilars: new CRL for Biocon, new deal for Meitheal/Tonghua Dongbao

Home/Pharma News | Posted 21/11/2023

In a dynamic landscape of pharmaceutical developments, Biocon Biologics (Biocon) faces a regulatory hurdle with a complete response letter from the US Food and Drug Administration (FDA), while Meitheal Pharmaceuticals expands its reach through a strategic licensing agreement with Tonghua Dongbao Pharmaceutical.

Abbott and mAbxience partnership for biosimilars in emerging markets

Home/Pharma News | Posted 14/11/2023

Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.

Fresenius Kabi and Formycon reach agreement with J&J, Alvotech and Teva expand partnership

Home/Pharma News | Posted 08/09/2023

In August 2023, Fresenius Kabi and Formycon announced that they have entered into a settlement agreement with Johnson & Johnson (J&J) concerning FYB202, a proposed ustekinumab biosimilar in the US. This followed the late July 2023 news that Alvotech and Teva Pharmaceuticals (Teva) have agreed to expand their existing strategic partnership agreement.

Cuba and China strengthen ties in biotechnology

Home/Pharma News | Posted 31/08/2023

The biotechnological cooperation between Cuba and China has been a longstanding relationship in the scientific and technological realms. For the benefit of both countries, Havana and Beijing have undertaken various collaborations in the field of biotechnology, driven by their bilateral relations and shared interest in the development of the healthcare and pharmaceutical industry.

New BioFactura-CuraTeQ partnership for ustekinumab biosimilar

Home/Pharma News | Posted 24/08/2023

CuraTeQ Biologics Private Limited, a subsidiary of India’s Aurobindo Pharma Limited, has entered into an exclusive license agreement to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (ustekinumab).

Four drugmakers sue the US government over the Inflation Reduction Act

Home/Pharma News | Posted 17/08/2023

In July 2023, Johnson & Johnson became the fourth large drugmaker to sue the US government over drug price negotiations in the Inflation Reduction Act (IRA). They join, Merck, Bristol Myers Squibb and Astellas in claiming that price negotiations by Medicare violate the First and Fifth Amendments of the US Constitution.

Celltrion–Rani partnership for RaniPill biosimilars

Home/Pharma News | Posted 14/07/2023

Celltrion and Rani Therapeutics (Rani) have entered a partnership under which Celltrion will supply ustekinumab and adalimumab biosimilars for RaniPill products under an exclusive license and supply agreement.

Cuba strengthens biotech industry through Eurasian partnerships

Home/Pharma News | Posted 14/07/2023

Cuba is consolidating its position in the field of biotechnology thanks to cooperation with several Eurasian nations, in particular Russia and Belarus.

Biosimilars manufacturing facilities approved by EU and US

Home/Pharma News | Posted 06/06/2023

Two biological drugs manufacturing facilities for biosimilar epoetin alfa and biosimilar bevacizumab were approved in the US and Europe in May and April 2023, respectively.

Cuba and China strengthen scientific cooperation for the development of medical treatments

Home/Pharma News | Posted 30/05/2023

In recent years, Cuba and China have established agreements to develop innovative medical treatments, notably Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB) and Center for Molecular Immunology (Centro de Inmunología Molecular, CIM), and have shared their experiences in the field of medical research.

HK inno.N–mAbxience partnership in Korea and Coherus advances in the US

Home/Pharma News | Posted 17/02/2023

In early 2023, it was announced that South Korea’s HK inno.N signed an exclusive license agreement with Spain's mAbxience to bring a denosumab biosimilar to market in South Korea. In addition, in the US, Coherus BioSciences is to acquire exclusive commercial rights to Formycon’s under-development Eylea (aflibercept) biosimilar.

Global marketing and commercialization advances for Alvotech and partners

Home/Pharma News | Posted 27/01/2023

In late 2022 and early 2023, Alvotech announced several strategic partnership advances to further their global reach as a biotech company specializing in the development and manufacture of biosimilar medicines.

New partnerships: Biocon-Yoshindo and Syna-Intas

Home/Pharma News | Posted 25/11/2022

Biocon Biologics announced on 17 October 2022 that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company Yoshindo for commercializing two of its pipeline biosimilar assets in Japan. Following this, on 2 November 2022, Syna Therapeutics signed an exclusive license agreement with Intas to commercialize a haematology biosimilar.

New funding to strengthen Cuba's biopharmaceutical industry

Home/Pharma News | Posted 18/11/2022

On 22 September 2022, the United Nations Development Programme (UNDP) announced the execution of a loan of Euros 46.7 million (US$45.25 million dollars) to support Cuba's biopharmaceutical industry and improve the country's capacity to respond against diseases such as COVID-19.

Similis-Blau biosimilars development partnership announced

Home/Pharma News | Posted 04/11/2022

On 25 October 2022, JSR Life Sciences (and LLC (JSR)) have announced that their recently launched biosimilars development branch, Similis Bio, has signed a development and license agreement with Brazilian firm, Blau Farmacêutica.

GaBI news digest for 14 October 2022

Home/Pharma News | Posted 14/10/2022

Selected news for the week of 14 October 2022 for GaBI readers.

FDA inspections in Iceland and Singapore for Alvotech and Strides

Home/Pharma News | Posted 14/10/2022

On 5 September 2022, Alvotech announced that it had received communication from the US Food and Drug Administration (FDA) that detailed the assessment of their Icelandic manufacturing facility and Alvotech’s subsequent written responses to FDA. This followed Strides announced the successful FDA inspection of their Singapore facility in early August 2022.

Novartis is set to spin-off Sandoz

Home/Pharma News | Posted 16/09/2022

Big pharma company Novartis announced on 25 August 2022 that it will spin off its generics and biosimilars arm, Sandoz.

New partnerships: Prestige-Intas and Samsung Bioepis-Samil

Home/Pharma News | Posted 02/09/2022

Prestige Biopharma (Prestige) and Intas Pharmaceuticals have entered a partnership to supply and commercialize Prestige Biopharma’s bevacizumab biosimilar in a number of countries globally. In addition, Samsung Bioepis has partnered with Samil to market their Lucentis (ranibizumab) biosimilar for ophthalmic diseases in South Korea.

Organon–Henlius partnership: biosimilars for women’s health

Home/Pharma News | Posted 24/06/2022

Organon, a global specialist in women’s health and expert in biosimilar commercialization, announced in mid-June 2022 that it had entered into an agreement with Shanghai Henlius Biotech, Inc. As part of this, Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab), and Prolia/Xgeva (denosumab) and will have global rights except for in China and its territories.

EMA authorizations: CRO generics suspended and Herceptin biosimilar refused

Home/Pharma News | Posted 17/06/2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorizations of several generics medicines tested by Synchron Research Services on 20 May 2022. The committee also refused the marketing authorization for BioPharma’s Herceptin biosimilar, Tuznue, on 19 May 2022.

Lupin–Yabao partnership to bring paediatric medicines to China

Home/Pharma News | Posted 20/05/2022

In April 2022, global pharmaceutical company, Lupin announced that it has entered a strategic partnership with China’s Yabao Pharmaceutical Company. Together, the companies will work to meet the growing demand for quality drugs with paediatric formulations in Chinese markets.

Biosimilar Solutions to start trials of biosimilar filgrastim and GMP manufacturing

Home/Pharma News | Posted 16/05/2022

In late-March and mid-April 2022, Biosimilar Solutions Inc (Biosimilar Solutions) announced the start of its registrational clinical trials for BSC1020 and BSC0826 biosimilar filgrastim and on 14 March 2022, OcyonBio LLC (OcyonBio) announced a manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions in Puerto Rico.

Aurobindo acquires Veritaz and Formycon–ATHOS partnership

Home/Pharma News | Posted 22/04/2022

In April 2022, Indian drugmaker, Aurobindo Pharma, acquired formulations business Veritaz. In addition, biosimilars specialist, Formycon, signed a partnership deal with ATHOS to merge development activities surrounding two biosimilars.

Fresenius Kabi acquire mAbxience and Ivenix

Home/Pharma News | Posted 15/04/2022

Fresenius Kabi is acquiring a majority stake in biosimilars company mAbxience, and is acquiring infusion pump maker, Ivenix outright. The deals are set to be completed by mid-2022.

Cipla–mAbxience partnership in South Africa

Home/Pharma News | Posted 08/04/2022

Cipla Medpro announced a partnership agreement with the global biotechnology company mAbxience in March 2022. This aims to provide essential oncology and respiratory-related biosimilars in South Africa.

Biocon to acquire biosimilars business from Viatris

Home/Pharma News | Posted 01/04/2022

India-based biologicals specialist Biocon Biologics (Biocon) announced on 28 February 2022 that it has entered into a definitive agreement with its partner Viatris (formerly Mylan) to acquire the latter’s biosimilar business.

Private equity firms poised to bid for Sandoz takeover

Home/Pharma News | Posted 25/03/2022

Following the late 2021 reports that Novartis is considering a possible sale or spinoff of its generics (and biosimilars) unit, Sandoz [1, 2], two private equity firms are now reportedly discussing a joint bid for the unit.

AbbVie and Alvotech settle Humira (adalimumab) disputes

Home/Pharma News | Posted 18/03/2022

US firm AbbVie and Iceland-based Alvotech have announced a resolution to the patent and trade secret disputes regarding Humira (adalimumab), for which Alvotech is developing a biosimilar.

Biogen and Xbrane form agreement for arthritis biosimilar

Home/Pharma News | Posted 04/03/2022

Biogen and Xbrane Biopharma (Xbrane) have announced a commercialization and licensing agreement for a biosimilar of certolizumab pegol (Cimzia), which can be used to treat rheumatoid arthritis and other inflammatory conditions.

Axantia to market Lupin’s pegfilgrastim in the Middle East and North Africa

Home/Pharma News | Posted 25/02/2022

On 1 February 2022, Indian multinational pharmaceutical company Lupin Ltd announced that it was entering into a License, Supply and Technology Sharing agreement with Axantia, to market Lupin’s pegfilgrastim biosimilar in certain territories in the Middle East and North Africa.

Orion-CuraTeQ and Theramax-Enzene Biosciences partnerships

Home/Pharma News | Posted 18/02/2022

In January 2022, Finnish company Orion Corporation and CuraTeQ Biologics, subsidiary of India’s Aurobindo Pharma, announced their European expansion to the Baltic countries. This follows the December 2021 announcement that the UK’s Theramex entered into an agreement with India’s Enzene Biosciences to develop, register and commercialize a biosimilar of Roche’s RoActemra® (tocilizumab).

Biocon–Viatris merger expected

Home/Pharma News | Posted 11/02/2022

The merger of India’s Biocon Biologics and Viatris’ biosimilar business are reported to be in advanced stages.

Samsung to take full control of Samsung Bioepis

Home/Pharma News | Posted 04/02/2022

Korean electronics giant Samsung has made a deal with US biotechnology company Biogen Idec (Biogen) to take full ownership of their joint biosimilars venture, Korea-based Samsung Bioepis.

Fresh partnerships announced for ranibizumab and trastuzumab biosimilars

Home/Pharma News | Posted 21/01/2022

Prestige BioPharma has partnered with Dr Reddy’s Laboratories (Dr Reddy’s) to commercialize their trastuzumab biosimilar, HD201, while MS Pharma has joined up with Formycon for the commercialization of its ranibizumab biosimilar, FYB201.

Spinoff updates: Merck’s Organon and Novartis’ Sandoz

Home/Pharma News | Posted 26/11/2021

Merck spinoff Organon has announced third quarter revenue of US$1.6 billion in 2021. This shows slight decline in women’s health medications but growth in biosimilar sales. Following its 2021 third quarter review, Novartis is considering the spinoff of its biosimilar division, Sandoz, as a standalone company.

Swiss Social Democrat’s for nationalization of Sandoz

Home/Pharma News | Posted 19/11/2021

In November 2021, the Social Democratic party in Switzerland urged the government to buy Novartis AG’s generics and biosimilars unit, Sandoz.

Biocon Biologics and Serum Institute Life Sciences partnership

Home/Pharma News | Posted 12/11/2021

On 16 September 2021, a strategic partnership was announced between India-based biologicals specialist Biocon Biologics Limited (BBL), and Indian vaccine manufacturer Serum Institute Life Sciences (SILS), a subsidiary of Serum Institute of India Pvt Ltd.

Ustekinumab biosimilars: new international biopharma agreements

Home/Pharma News | Posted 12/11/2021

September and October 2021 saw new international agreements between biopharmaceutical companies regarding ustekinumab biosimilars. These were formed between BioFactura and Rani Therapeutics in the US, and China’s Bio-Thera Solutions and Pharmapark in Russia.

Agreement to produce similar biotherapeutic product in Turkey

Home/Pharma News | Posted 05/11/2021

On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country.

Collaborations to commercialize oncology biosimilars

Home/Pharma News | Posted 22/10/2021

New collaborations to commercialize oncology biosimilars have been announced between Sandoz and Bio-Thera Solutions, and between Innovent Biologics and Ascentage Pharma.

Licensing agreements signed for ustekinumab biosimilars

Home/Pharma News | Posted 17/09/2021

Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals.

Oncogen–BrightGene partnership

Home/Pharma News | Posted 10/09/2021

In June 2021, Malaysian oncology generics company, Oncogen, and China’s BrightGene Bio-Medical Technology announced that they are partnering to develop, manufacture, market and distribute generic drug products for the US market.

Menagen–CKD Middle Eastern partnership

Home/Pharma News | Posted 03/09/2021

Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.

Teva signs deal with Bioeq for ranibizumab biosimilar FYB201

Home/Pharma News | Posted 30/07/2021

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Swiss biotechnology company Bioeq AG announced on 28 June 2021 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s candidate ranibizumab biosimilar (FYB201) in Europe, Canada, Israel and New Zealand.

Organon launches as new global women’s health company and appoints leaders in Latin America

Home/Pharma News | Posted 23/07/2021

Organon celebrated its launch as a global women’s health company on 3 June 2021 with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange.

Prestige-Cytiva partnership and new Korean R & D facility

Home/Pharma News | Posted 09/07/2021

Singapore-based Prestige BioPharma, which specializes in the development of antibody therapeutics, is to build a new research and development (R & D) facility in the Republic of Korea and has entered a strategic partnership with Cytiva.

Theramex to market Prolia biosimilar in Europe and Australia

Home/Pharma News | Posted 25/06/2021

UK-based pharmaceutical company Theramex UK Ltd, which focuses on women’s health, has announced an agreement with India’s Enzene Biosciences Limited for the registration and commercialisation of a Prolia (denosumab) biosimilar in Europe and Australia.

AbbVie antitrust investigation and Sandoz biosimilar delay

Home/Pharma News | Posted 04/06/2021

In May 2021, following the release of a report, it was announced that AbbVie is likely to be subject to an antitrust investigation due to claims it has delayed market entry of biosimilars of Humira (adalimumab). Alvotech also raised a complaint against AbbVie after being sued over their Humira biosimilar application. In addition, the US Supreme Court denied Sandoz the ability to release its Enbrel (etanercept) biosimilar.

Merck partners with Indian drugmakers to increase access to COVID-19 drug

Home/Pharma News | Posted 21/05/2021

On 27 April 2021, Merck & Co Inc (also known as MSD Pharmaceuticals) announced that it had partnered with five Indian generic drug manufacturers to expand production and access to its experimental COVID-19 drug.

Bevacizumab and insulin aspart non-originator biologicals to be sold in Russia

Home/Pharma News | Posted 14/05/2021

Singapore-based Prestige Biopharma (Prestige) has formed an agreement with Russian company Pharmapark to commercialize Prestige’s bevacizumab non-originator biological in Russia. Russian company Geropharm has also launched an insulin aspart non-originator biological on the market in the country.

Huons Lab and PanGen Biotech to develop denosumab biosimilar

Home/Pharma News | Posted 30/04/2021

On 20 April 2021, Korean pharmaceutical company, Huons Lab, announced the development of a denosumab biosimilar to treat osteoporosis. The company is working with PanGen Biotech and using their cell line culturing and purification technology.

PlantForm and partners in Brazil to develop pembrolizumab biosimilar

Home/Pharma News | Posted 23/04/2021

Canada-based PlantForm Corporation (PlantForm) have signed an agreement with partners in Brazil to develop a biosimilar of the cancer treatment pembrolizumab (Keytruda).